Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database

BackgroundThis study evaluates the risk of dermatologic adverse events (AEs) associated with aromatase inhibitors (AIs) through an analysis of data from the FDA Adverse Event Reporting System (FAERS).MethodsFAERS data from Q1 2004 to Q2 2024 were analyzed for dermatologic AEs related to AIs. A dispr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuan-Yuan Wu, Qiong-Lian Huang, Zhan-Yang Luo, Xiao-Yun Song, You-Yang Shi, Jin-Zhou Zheng, Sheng Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Pharmacology
Subjects:	aromatase inhibitors dermatologic adverse events FDA adverse event reporting system disproportionality analysis real-world
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1529342/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Adverse events reporting of edaravone: a real-world analysis from FAERS database
by: Qi Shang, et al.
Published: (2025-03-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

A real-world data analysis of montelukast in FDA Adverse Event Reporting System (FAERS) database
by: Hesen Huang, et al.
Published: (2025-07-01)

Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database
by: Ye Hu, et al.
Published: (2025-02-01)

A comparative analysis of drug-induced kidney injury adverse reactions between cyclosporine and tacrolimus based on the FAERS database
by: Min Xu, et al.
Published: (2025-05-01)

Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
by: Bingqing Wang, et al.
Published: (2025-05-01)

Mogamulizumab‐Associated Autoimmune Diseases: Insights From FAERS Database Analysis
by: Genshan Zhang, et al.
Published: (2024-12-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases
by: Tao Wang, et al.
Published: (2025-04-01)

Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004–2023)
by: Lin Chen, et al.
Published: (2024-11-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Drug-induced cardiac arrest: a pharmacovigilance study from 2004–2024 based on FAERS database
by: Gaocan Ren, et al.
Published: (2025-05-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases
by: Zhaorui Wang, et al.
Published: (2025-03-01)

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2025-05-01)

Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database
by: Yanping Shu, et al.
Published: (2024-12-01)

Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database
by: Ping Li, et al.
Published: (2025-07-01)

Analysis and mining of brodalumab adverse events based on FAERS database
by: Yue Wan, et al.
Published: (2025-05-01)

Risk assessment of the top 50 drugs associated with drug-induced orthostatic hypotension: a disproportionality analysis of the FAERS and JADER databases
by: Gaocan Ren, et al.
Published: (2025-03-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database
by: Yu Lin, et al.
Published: (2025-08-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)

Evaluation of post-market adverse events of lubiprostone: a real-world adverse event analysis from the FAERS database
by: Qingqing Li, et al.
Published: (2025-05-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study
by: Tianyu Chen, et al.
Published: (2025-05-01)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
by: Sentai Wang, et al.
Published: (2025-03-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database
by: Jinlong Huang, et al.
Published: (2025-04-01)

An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System
by: Hang Chen, et al.
Published: (2025-06-01)

Potential adverse events of fluoxetine: a real-world study based on the FAERS database
by: Xuezheng Gao, et al.
Published: (2025-07-01)

A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system
by: Yong Yu, et al.
Published: (2025-02-01)

Analysis and mining of Dupilumab adverse events based on FAERS database
by: Hui Gao, et al.
Published: (2025-03-01)

Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01)

Adverse events following 9-valent human papillomavirus vaccine (GARDASIL® 9) reported to the Vaccine Adverse Event Reporting System (VAERS), 2015–2024
by: Qiong Liu, et al.
Published: (2025-12-01)

Safety assessment of temozolomidee: real-world adverse event analysis from the FAERS database
by: Yu Liu, et al.
Published: (2025-08-01)

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)